Corrigendum: A Recombinant Human Adenovirus Type 5 (H101) Combined With Chemotherapy for Advanced Gastric Carcinoma: A Retrospective Cohort Study

Ran Zhang, Yanxin Cui, Xin Guan and Xiang Jun Jiang*

Department of Gastroenterology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China

Keywords: H101, chemotherapy, advanced gastric carcinoma, survival, response rate

A Corrigendum on

A Recombinant Human Adenovirus Type 5 (H101) Combined With Chemotherapy for Advanced Gastric Carcinoma: A Retrospective Cohort Study

by Zhang R, Cui Y, Guan X and Jiang X (2021) Front. Oncol. 11:752504. doi: 10.3389/fonc.2021.752504

In the original article, there were three errors in the text.

Firstly, the dissolution of H101 was incorrectly stated. A correction has been made to Materials and Methods section, “Treatment Procedures”, Paragraph 1:

“H101 (-20°C, Shanghai Sunway Biotech, Shanghai, China) was then dissolved with normal saline to 30% of the estimated tumor volume at room temperature, was peritumorally injected via endoscopy according to the manufacturer’s instructions, and these injections were repeated 21 days as one treatment cycle”.

Secondly, the dose of H101 for patients with one lesion with a maximum diameter of ≤5 cm was incorrectly stated. A correction has been made to Materials and Methods section, “Treatment Procedures”, Paragraph 2:

“The doses of H101 depended on tumor size and the number of lesions: (1) 0.5 × 10^{12} virus particles (vp)/day (1 unit) for patients with one lesion with a maximum diameter of ≤5 cm; (2) 1.0 × 10^{12} vp/day (2 units) for patients with one lesion with a maximum diameter of 5-10 cm or two lesions with a sum of the diameters of 5-10 cm; (3) 1.5 × 10^{12} vp/day (3 units) for patients with one lesion with a maximum diameter >10 cm or ≥ three lesions; (4) for patients with two or more lesions, the dose of H101 for each lesion was further decided by the proportion and size of the different lesions. The number of cycles of H101 was determined according to the instructions for the use of H101 and patients’ effect after injection. After injection of H101, renin (0.1 mg/ml) and thrombin (10-100 unit/mL) were sprayed to stop the bleeding”.

Citation:
Zhang R, Cui Y, Guan X and Jiang XJ (2022) Corrigendum: A Recombinant Human Adenovirus Type 5 (H101) Combined With Chemotherapy for Advanced Gastric Carcinoma: A Retrospective Cohort Study. Front. Oncol. 12:841156. doi: 10.3389/fonc.2022.841156
Thirdly, the statistical comparison of CR and PD between group A and group C was incorrectly stated. A correction has been made to Results section, “Clinical Outcomes and Follow-Up”, Paragraph 1:

“Whereas, the combination of H101 injection with chemotherapy in group C (n = 32 cases, four CRs and six PDs) was more effective than H101 injection alone in group A (all \( p < 0.05 \), Table 2).”

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.